Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative therapies work by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these substances boost insulin production and suppress gluca

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight reduction – they exhibit intriguing differences in t